PMGC Holdings Inc. - SIC # 2840 -

Ticker Exchange SIC # Website Latest Ticker
ELAB Nasdaq 2840 pmgcholdings.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for PMGC Holdings Inc.

PMGC Holdings Inc. Announces Closing of Elevai Skincare Divestiture - Jan 16th, 2025 1:31 pm
PMGC Holdings Inc. Announces Name Change of Wholly Owned Subsidiaries - Jan 15th, 2025 2:30 pm
PMGC Holdings Inc. Following Skincare Subsidiary Sale, Embarks on Bold Growth Strategy - Jan 2nd, 2025 8:55 pm
Carmell Announces Execution of Definitive Agreement to Acquire Elevai Skincare, a leader in Physician Dispensed Exosome Skin and Hair Care Products - Jan 2nd, 2025 1:00 pm
Elevai Labs plans name change to PMGC Holdings, redomicile to Nevada - Dec 21st, 2024 12:40 pm
Elevai Labs Inc. Announces Name Change to PMGC Holdings Inc. and Redomicile to Nevada - Dec 21st, 2024 12:30 am
Elevai Labs Inc. Announces Anticipated Name Change to PMGC Holdings Inc. and Redomicile to Nevada - Dec 20th, 2024 12:30 pm
Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Announces FDA Regulatory Pathway for EL-22, a Pioneering Obesity Therapy Targeting Fat Loss and Muscle Preservation - Dec 9th, 2024 1:00 pm
Elevai Labs Inc. Subsidiary, Elevai Skincare, Launches S-Series Root Renewal System, Marking Entry into Hair Care Market - Dec 6th, 2024 12:30 pm
Elevai Labs Inc. Announces Record-Breaking Sales Month in 2024 for Elevai Skincare Division - Dec 4th, 2024 1:00 pm
Elevai Labs Inc. Announces Reverse Stock Split to Maintain Nasdaq Listing Compliance - Nov 22nd, 2024 11:23 pm
Elevai Labs Inc. Announces Withdrawal of Offer to Exchange and Plans to Reassess - Nov 22nd, 2024 10:00 pm
Elevai Labs Third Quarter 2024 Earnings: US$0.068 loss per share (vs US$0.078 loss in 3Q 2023) - Nov 17th, 2024 2:29 pm
CORRECTION - Elevai Labs Inc. - Nov 14th, 2024 7:35 pm
Elevai Labs Inc. Reports Financial Results for the Second Fiscal Quarter of 2024 and Provides Business Update - Nov 14th, 2024 2:08 pm
Elevai Labs Inc. Announces Update and Extension of Pending Offer to Exchange - Nov 4th, 2024 10:45 pm
Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Engages Leading Contract Research Organization (CRO) to Support Regulatory Planning Efforts and Pre-IND Meeting with the Food and Drug Administration For EL-22 For The Treatment of Obesity - Oct 22nd, 2024 1:54 pm
Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Highlights Past Positive Preclinical Data Showing Potential of EL-32, A Dual Myostatin & Activin-A Blocker, For the Treatment of Obesity - Oct 21st, 2024 11:30 am
Elevai Labs Inc. Commences Offer to Exchange Up to 15,000,000 shares of Common Stock For Shares of Non Tradable. Locked Up Series B Preferred Stock - Oct 4th, 2024 9:08 pm
Sector Update: Health Care Stocks Fall Late Afternoon - Oct 3rd, 2024 7:53 pm